Related Experiment Video

Updated: Aug 31, 2025

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.4K

Programmed prodrug breaking the feedback regulation of P-selectin in plaque inflammation for atherosclerotic therapy

Quan Wang1, Hongshu Jing2, Jun Lin3

  • 1State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200032, China.

Biomaterials
|August 24, 2022
PubMed

Insights

New nanoparticles target P-selectin to combat arteriosclerosis. This programmed prodrug effectively reduces inflammation and plaque in mice, offering a promising therapeutic strategy for this cardiovascular disease.

Area of Science:

  • Cardiovascular Research
  • Nanomedicine
  • Inflammation Biology

Background:

  • Arteriosclerosis progression is driven by complex plaque inflammation.
  • Current treatments targeting single pathways show limited efficacy.
  • P-selectin is highly expressed on plaque endothelial cells in patients.

Purpose of the Study:

  • To develop a novel anti-inflammatory agent for arteriosclerosis.
  • To investigate the efficacy of low molecular weight heparin-indomethacin nanoparticles (LI NPs) in targeting P-selectin.
  • To evaluate the therapeutic potential of LI NPs in an arteriosclerosis model.

Main Methods:

  • Programmed prodrug LI NPs synthesized via esterification of low molecular weight heparin and indomethacin.
  • In vitro assessment of LI NPs' anti-inflammatory functions, including macrophage adhesion inhibition and apoptosis induction.
  • In vivo evaluation of LI NPs in an arteriosclerosis mouse model.

Main Results:

  • LI NPs demonstrated biocompatibility and applicability without additives.
  • LI NPs effectively interfered with P-selectin, reducing inflammatory factor secretion and inducing macrophage apoptosis.
  • Significant reduction in plaque area and satisfactory therapeutic effect observed in the arteriosclerosis mice model.

Conclusions:

  • Programmed prodrug LI NPs offer a multiphase inhibition strategy for arteriosclerosis.
  • LI NPs show promise for clinical therapy by intervening in endothelial cell-macrophage interactions.
  • Targeting P-selectin with LI NPs presents a novel approach to managing arteriosclerosis.
Keywords:
Anti-Arteriosclerosis nanoparticlesIndomethacinLow molecular weight heparinP-selectinProdrug

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.3K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.7K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
619
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
27
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
26
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
248
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K